BR112016027845A2 - proteínas de fusão de ox40l e usos das mesmas - Google Patents

proteínas de fusão de ox40l e usos das mesmas

Info

Publication number
BR112016027845A2
BR112016027845A2 BR112016027845A BR112016027845A BR112016027845A2 BR 112016027845 A2 BR112016027845 A2 BR 112016027845A2 BR 112016027845 A BR112016027845 A BR 112016027845A BR 112016027845 A BR112016027845 A BR 112016027845A BR 112016027845 A2 BR112016027845 A2 BR 112016027845A2
Authority
BR
Brazil
Prior art keywords
fusion polypeptide
fusion proteins
polypeptide subunits
domain
methods
Prior art date
Application number
BR112016027845A
Other languages
English (en)
Inventor
Feng Hui
Damschroder Melissa
Oberst Michael
Hammond Scott
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of BR112016027845A2 publication Critical patent/BR112016027845A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a divulgação proporciona subunidades polipeptídicas de fusão de ox40l huigg4 compreendendo o domínio fc da igg4 humana, um domínio de trimerização, e o domínio de ligação do receptor do ligante do ox40, onde as subunidades polipeptídicas de fusão podem se montar em proteínas hexaméricas. também são proporcionados métodos para efetuar subunidades polipeptídicas de fusão e proteínas hexaméricas, e métodos de uso, por exemplo, tratamento de câncer.
BR112016027845A 2014-05-29 2015-05-27 proteínas de fusão de ox40l e usos das mesmas BR112016027845A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004555P 2014-05-29 2014-05-29
US201562111796P 2015-02-04 2015-02-04
PCT/US2015/032598 WO2015183902A1 (en) 2014-05-29 2015-05-27 Ox40l fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
BR112016027845A2 true BR112016027845A2 (pt) 2017-10-31

Family

ID=53540957

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016027845A BR112016027845A2 (pt) 2014-05-29 2015-05-27 proteínas de fusão de ox40l e usos das mesmas

Country Status (10)

Country Link
US (1) US9718870B2 (pt)
EP (1) EP3148573A4 (pt)
JP (1) JP6666267B2 (pt)
CN (1) CN106456734A (pt)
BR (1) BR112016027845A2 (pt)
GB (1) GB2532817A (pt)
MX (1) MX360295B (pt)
RU (1) RU2016150096A (pt)
TW (1) TW201623327A (pt)
WO (1) WO2015183902A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016027845A2 (pt) * 2014-05-29 2017-10-31 Medimmune Llc proteínas de fusão de ox40l e usos das mesmas
HUE049982T2 (hu) 2014-11-14 2020-11-30 Hoffmann La Roche TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák
AU2016215175B2 (en) 2015-02-06 2021-09-16 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
JP6996979B2 (ja) 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
US11536716B2 (en) * 2015-06-25 2022-12-27 Hoffmann-La Roche Inc. Cell based assay for determining antibody or ligand binding and function
EP3334758A1 (en) 2015-08-12 2018-06-20 Medimmune Limited Gitrl fusion proteins and uses thereof
SG10201913576RA (en) 2015-10-01 2020-02-27 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
EP3243836A1 (en) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
US10331232B2 (en) * 2016-10-27 2019-06-25 Fluidity Technologies, Inc. Controller with situational awareness display
US10331233B2 (en) * 2016-10-27 2019-06-25 Fluidity Technologies, Inc. Camera and sensor controls for remotely operated vehicles and virtual environments
WO2018107125A1 (en) * 2016-12-09 2018-06-14 Seattle Genetics, Inc. Bivalent antibodies masked by coiled coils
JP2020504105A (ja) * 2016-12-19 2020-02-06 グレンマーク・ファーマシューティカルズ・エスエー 新規なｔｎｆｒアゴニストおよびその使用
WO2018157163A1 (en) 2017-02-27 2018-08-30 Shattuck Labs, Inc. Vsig8-based chimeric proteins
BR112019017298A2 (pt) 2017-02-27 2020-04-14 Shattuck Labs Inc proteínas quiméricas à base de tigit e light
US11267856B2 (en) 2017-02-27 2022-03-08 Shattuck Labs, Inc. CSF1R-CD40L chimeric proteins
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
EP3628070B1 (en) * 2017-04-28 2021-09-08 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides for use in increasing central memory t cells
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
CN109839509A (zh) * 2019-02-15 2019-06-04 浠思（上海）生物技术有限公司 利用ox40/ox40l的htrf结合分析实验技术筛选潜在激动剂的方法
US20230183366A1 (en) * 2020-05-13 2023-06-15 Inserm (Institut National De La Santé Et De La Recherch Médicale) Recombinant proteins with ox40 activating properties
EP4277639A2 (en) * 2021-01-15 2023-11-22 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Hybrid and truncated immune cell proteins
CN118234851A (zh) * 2021-11-19 2024-06-21 南开大学 重组武装溶瘤病毒组合物及其在til过继治疗中的用途
CN114966061B (zh) * 2022-07-28 2022-10-21 中国食品药品检定研究院 一种抗ox40抗体的生物活性检测方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US7056695B2 (en) * 2000-03-02 2006-06-06 Xencor TNF-α variants
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
AU2003210806A1 (en) * 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
US8911726B2 (en) * 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
AU2013263717B2 (en) * 2005-05-06 2016-05-19 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
EP2650020B1 (en) * 2005-05-06 2016-08-24 Providence Health & Services - Oregon Trimeric OX40-immunoglobulin fusion protein and methods of use
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
JP5564181B2 (ja) * 2005-12-08 2014-07-30 シルワン，ハヴァル 免疫刺激組成物および方法
BRPI0811857A2 (pt) * 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
US20100267934A1 (en) * 2007-05-31 2010-10-21 Genmab A/S Stable igg4 antibodies
US8637637B2 (en) * 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
GB201014033D0 (en) * 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
US20150157710A1 (en) * 2012-03-02 2015-06-11 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Dual ox40 agonist/il-2 cancer therapy methods
BR112016027845A2 (pt) * 2014-05-29 2017-10-31 Medimmune Llc proteínas de fusão de ox40l e usos das mesmas
CN107106590B (zh) * 2014-10-24 2022-10-18 阿斯利康(瑞典)有限公司 组合

Also Published As

Publication number Publication date
EP3148573A1 (en) 2017-04-05
CN106456734A (zh) 2017-02-22
JP2017519494A (ja) 2017-07-20
EP3148573A4 (en) 2017-11-15
RU2016150096A3 (pt) 2019-01-24
MX2016014647A (es) 2017-05-30
WO2015183902A1 (en) 2015-12-03
US9718870B2 (en) 2017-08-01
TW201623327A (zh) 2016-07-01
JP6666267B2 (ja) 2020-03-13
RU2016150096A (ru) 2018-07-02
MX360295B (es) 2018-10-29
GB2532817A (en) 2016-06-01
GB201509062D0 (en) 2015-07-08
US20160024176A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
BR112016027845A2 (pt) proteínas de fusão de ox40l e usos das mesmas
BR112018002039A2 (pt) proteínas de fusão gitrl e usos das mesmas
BR112017016705A2 (pt) agentes de ligação a tnfrsf e uso dos mesmos
BR112017025529A2 (pt) agentes de ligação ao tigit e usos destes
EP3733716A4 (en) DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE
BR112017006178A2 (pt) região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
CL2019000261A1 (es) Polipéptidos modificados y usos de los mismos.
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
SV2017005548A (es) Proteinas de fusion
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
EA202190903A2 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
DK3468568T3 (da) Ekstracellulære vesikler der er afledt af humantrombo-cytlysat, til anvendelse i medicin
EP3390443A4 (en) ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANTS OF FC REGIONS, AND METHODS OF USE
DK4095130T3 (da) Mærkede hæmmere af prostataspecifikt membranantigen (psma), deres anvendelse som billeddannelsesmidler og farmaceutiske midler til behandling af prostatacancer
GT201700102A (es) Conjugados de anticuerpo-fármaco
DK3298033T4 (da) Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
DK3655006T3 (da) Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse deraf
BR112015013127A2 (pt) imunoterapia com agentes de ligação
EP3240804A4 (en) ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
BR112017010324A2 (pt) método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
MY191944A (en) Binding proteins and methods of use thereof
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements